Veru Reports Fiscal 2024 Second Quarter Financial Results and Progress of its Enobosarm High Quality Weight Loss Clinical Program
May 08, 2024 06:30 ET
|
Veru Inc.
--Phase 2b clinical study of enobosarm in combination with semaglutide (Wegovy®*) for high quality weight loss is actively enrolling-- --Company assembles esteemed high quality weight loss Scientific...
Anti-Obesity Drugs Global Strategic Business Report 2024: Market to Reach $4.8 Billion by 2030 - Saxenda Commands the AOM Market, Newer Drugs to Provide Impetus to Market Growth
May 07, 2024 10:41 ET
|
Research and Markets
Dublin, May 07, 2024 (GLOBE NEWSWIRE) -- The "Anti-Obesity Drugs - Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering.Global Anti-Obesity Drugs Market to...
NowVertical Group Reports Fourth Quarter and Full Year 2023 Financial Results
May 07, 2024 09:08 ET
|
NowVertical Group Inc
TORONTO, May 07, 2024 (GLOBE NEWSWIRE) -- NowVertical Group Inc. (TSX-V: NOW) (OTCQB: NOWVF) (“NOW” or the “Company”), a leading data analytics and AI solutions company, today announced audited...
Vect-Horus participera à une table ronde lors de la conférence Viva Technology
May 07, 2024 03:00 ET
|
Vect-Horus
Marseille, France, 7 Mai - VECT-HORUS, l'entreprise de biotechnologie qui conçoit et développe des molécules « vecteurs » qui facilitent l’adressage de molécules thérapeutiques ou d’agents d’imagerie...
Vect-Horus to Take Part in a Roundtable Discussion at Viva Technology Conference
May 07, 2024 03:00 ET
|
Vect-Horus
Marseille, France, May 7th - Vect-Horus, a privately held biotechnology company that designs and develops molecular vectors that facilitate the targeted delivery of therapeutic molecules and imaging...
Trading in Novo Nordisk shares by board members, executives and associated persons
May 06, 2024 15:02 ET
|
Novo Nordisk A/S
Bagsværd, Denmark, 06 May 2024 – This company announcement discloses the data of the transaction(s) made in Novo Nordisk shares by the company’s board members, executives and their associated persons...
Novo Nordisk A/S - share repurchase programme
May 06, 2024 14:44 ET
|
Novo Nordisk A/S
Bagsværd, Denmark, 06 May 2024 – The execution of Novo Nordisk A/S’ overall share repurchase programme for 2024 of DKK 20 billion continues. As part of this, Novo Nordisk A/S has now initiated a new...
Novo Nordisk A/S purchases B shares worth DKK 5,428 million from Novo Holdings A/S under the 2024 share repurchase programme
May 06, 2024 14:40 ET
|
Novo Nordisk A/S
Bagsværd, Denmark, 06 May 2024 – Today, Novo Nordisk A/S has entered into an agreement to purchase 6,311,250 B shares of DKK 0.10 at a value of DKK 5,427,801,225.00 million from Novo Holdings A/S. The...
Global Liver Disease Therapeutics Market to Grow Rapidly by 2030, Examines DelveInsight | Key Players in the Market - AbbVie, GSK, F.Hoffmann-La Roche, Bristol-Myers Squibb Company, Abbott, Gilead Sciences, Astellas Pharma
May 06, 2024 13:00 ET
|
DelveInsight Business Research LLP
New York, USA, May 06, 2024 (GLOBE NEWSWIRE) -- Global Liver Disease Therapeutics Market to Grow Rapidly by 2030, Examines DelveInsight | Key Players in the Market - AbbVie, GSK, F.Hoffmann-La...
Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons
May 03, 2024 13:48 ET
|
Novo Nordisk A/S
Bagsværd, Denmark, 3 May 2024 — This company announcement discloses the data of the transaction(s) made in Novo Nordisk shares by the company’s board members, executives and their associated persons...